Tumor expression of adiponectin receptor 2 and lethal prostate cancer

Carcinogenesis

Volumn 36, Issue 6, 2015, Pages 639-647

  Rider, Jennifer R ^a   Fiorentino, Michelangelo ^c   Kelly, Rachel ^a   Gerke, Travis ^a   Jordahl, Kristina ^a   Sinnott, Jennifer A ^a   Giovannucci, Edward L ^a,b   Loda, Massimo ^d   Mucci, Lorelei A ^a   Finn, Stephen ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d HARVARD MEDICAL SCHOOL   (United States)

^e TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN RECEPTOR 2; FATTY ACID SYNTHASE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPOR2 PROTEIN, HUMAN; FASN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; BIOSYNTHESIS; BLOOD; CELL PROLIFERATION; COMPLICATION; DISEASE COURSE; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); OBESITY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; VERY ELDERLY;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOMARKERS, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FATTY ACID SYNTHASE, TYPE I; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OBESITY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ADIPONECTIN;

EID: 84941630019     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv048     Document Type: Article

References (50)

1. de Ferranti, S. et al. (2008) The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin. Chem., 54, 945-955.
2. Scherer, P.E. et al. (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem., 270, 26746-26749.
3. Berg, A.H. et al. (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab., 13, 84-89.
4. Cnop, M. et al. (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 46, 459-469.
5. Yamauchi, T. et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med., 8, 1288-1295.
6. Lu, J.P. et al. (2012) Adiponectin inhibits oxidative stress in human prostate carcinoma cells. Prostate Cancer Prostatic Dis., 15, 28-35.
7. Bub, J.D. et al. (2006) Adiponectin as a growth inhibitor in prostate cancer cells. Biochem. Biophys. Res. Commun., 340, 1158-1166.
8. Li, H. et al. (2010) A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin. Chem., 56, 34-43.
9. Dhillon, P.K. et al. (2011) Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 20, 2618-2627.
10. Fan, H.J. et al. (2013) Three adiponectin rs1501299G/T, rs822395A/C, and rs822396A/G polymorphisms and risk of cancer development: a meta-analysis. Tumour Biol., 34, 769-778.
11. Kaklamani, V. et al. (2011) Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism., 60, 1234-1243.
12. de Faria, A.P. et al. (2014) Adiponectin 11377C/G and +276G/T polymorphisms affect adiponectin levels but do not modify responsiveness to therapy in resistant hypertension. Basic Clin. Pharmacol. Toxicol. doi:10.1111/bcpt.12368. [Epub ahead of print].
13. Michalakis, K. et al. (2007) Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol. Biomarkers Prev., 16, 308-313.
14. Cheng, S.P. et al. (2013) Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem. Biophys., 65, 203-210.
15. Hiyoshi, M. et al. (2012) Adiponectin receptor 2 is negatively associated with lymph node metastasis of colorectal cancer. Oncol. Lett., 3, 756-760.
16. Byeon, J.S. et al. (2010) Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int. J. Cancer, 127, 2758-2767.
17. Gialamas, S.P. et al. (2011) Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism., 60, 1530-1538.
18. Shin, E. et al. (2013) Adiponectin receptor expression in gastric carcinoma: implications in tumor development and progression. J. Cancer Res. Clin. Oncol., 139, 709-718.
19. Jeong, Y.J. et al. (2011) Expression of leptin, leptin receptor, adiponectin, and adiponectin receptor in ductal carcinoma in situ and invasive breast cancer. J. Breast Cancer, 14, 96-103.
20. Howard, J.M. et al. (2010) Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br. J. Surg., 97, 1020-1027.
21. Christen, W.G. et al. (2000) Design of Physicians' Health Study II-a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann. Epidemiol., 10, 125-134.
22. Steering Committee of the Physicians' Health Study Research Group. (1989) Final Report on the Aspirin Component of the Ongoing Physicians' Health Study. N. Engl. J. Med., 321, 129-135.
23. Hennekens, C.H. et al. (1996) Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med., 334, 1145-1149.
24. Stark, J.R. et al. (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J. Clin. Oncol., 27, 3459-3464.
25. Faith, D.A. et al. (2004) Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate, 61, 215-227.
26. Allred, D.C. et al. (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol., 11, 155-168.
27. Nguyen, P.L. et al. (2010) Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J. Clin. Oncol., 28, 3958-3964.
28. Zu, K. et al. (2014) Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J. Natl Cancer Inst., 106, djt430.
29. Mucci, L.A. et al. (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals followup study. J. Clin. Oncol., 27, 5627-5633.
30. Pischon, T. et al. (2003) Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin. Chem., 49, 650-652.
31. Kelesidis, I. et al. (2006) Adiponectin and cancer: a systematic review. Br. J. Cancer, 94, 1221-1225.
32. Adya, R. et al. (2012) Protective actions of globular and full-length adiponectin on human endothelial cells: novel insights into adiponectininduced angiogenesis. J. Vasc. Res., 49, 534-543.
33. Jia, Z. et al. (2014) Adiponectin induces breast cancer cell migration and growth factor expression. Cell Biochem. Biophys., 70, 1239-1245.
34. Ouchi, N. et al. (2004) Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem., 279, 1304-1309.
35. Tang, C.H. et al. (2009) Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF-kappaB pathways. Prostate, 69, 1781-1789.
36. Cai, C. et al. (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell, 20, 457-471.
37. Gavin, J.R. 3rd et al. (1974) Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. Proc. Natl Acad. Sci. USA., 71, 84-88.
38. Madiehe, A.M. et al. (2000) Differential expression of leptin receptor in high- and low-fat-fed Osborne-Mendel and S5B/Pl rats. Obes. Res., 8, 467-474.
39. Touvier, M. et al. (2013) Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am. J. Epidemiol., 177, 3-13.
40. Stevens, V.L. et al. (2014) No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev., 23, 890-892.
41. Peters, K.E. et al. (2013) A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome. BMC Med. Genet., 14, 15.
42. Mather, K.J. et al. (2012) Common variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/2), adiponectin concentrations, and diabetes incidence in the Diabetes Prevention Program. Diabet. Med., 29, 1579-1588.
43. Civitarese, A.E. et al. (2004) Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia, 47, 816-820.
44. Yamauchi, T. et al. (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med., 13, 332-339.
45. Nakajima, A. et al. (2010) Molecular mechanisms linking adiponectin receptor signalling and cancer. Open Obes. J., 2, 43-49.
46. Araneta, M.R. et al. (2007) Adiponectin and ghrelin levels and body size in normoglycemic Filipino, African-American, and white women. Obesity (Silver Spring)., 15, 2454-2462.
47. Bush, N.C. et al. (2005) Adiponectin is lower among African Americans and is independently related to insulin sensitivity in children and adolescents. Diabetes, 54, 2772-2778.
48. Considine, R.V. et al. (2008) Adiponectin and leptin in African Americans. Obesity (Silver Spring)., 16, 428-434.
49. Okada-Iwabu, M. et al. (2013) A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature, 503, 493-499.
50. Holland, W.L. et al. (2013) Cell biology. Ronning after the adiponectin receptors. Science, 342, 1460-1461.